Ankit Mangla, MD
Hematology & Oncology · Cleveland, OHNPI 1871841908
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,958 of the $28,153 with a category attached, or 67.3%. 31 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 43.7% of the total. 2025 is the largest year on record at $16,460, more than ten times the $1,533 reported in 2019.
Across 81 payments — averaging $347.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$12K
- E.r. Squibb & Sons, L.L.C.$6K
- Springworks Therapeutics, Inc.$5K
- Deciphera Pharmaceuticals Inc.$3K
- Amgen$1K
- Merck$139
- plus $822 from 25 others
Across 1,266 payments — averaging $2626.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2.3M
- Boehringer Ingelheim$281K
- Novartis$258K
- Springworks Therapeutics, Inc.$206K
- Trillium Therapeutics USA, LLC$104K
- E.r. Squibb & Sons, L.L.C.$96K
- plus $81K from 4 others
What the payments were for
- Consulting fees$5,74520%
- Speaking & faculty fees$18,95867%
- Travel & lodging$1,4465%
- Food & beverage$1,9777%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 5 | $12,309 |
| E.r. Squibb & Sons, L.L.C. | 10 | $6,259 |
| Springworks Therapeutics, Inc. | 5 | $4,562 |
| Deciphera Pharmaceuticals Inc. | 6 | $2,847 |
| Amgen | 8 | $1,215 |
| Merck | 8 | $139 |
| Array Biopharma Inc | 2 | $109 |
| Novartis | 6 | $101 |
| Eisai Inc. | 4 | $89 |
| Novartis Pharma AG | 1 | $77 |
| AstraZeneca | 3 | $47 |
| Bayer | 2 | $37 |
| Pfizer | 2 | $32 |
| Seagen Inc. | 2 | $30 |
| Tempus AI, Inc | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| Sanofi | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Puma Biotechnology, Inc. | 1 | $19 |
| Foundation Medicine, Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $16 |
| Incyte Corporation | 1 | $16 |
| Epizyme, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Apellis Pharmaceuticals, Inc. | 1 | $15 |
| Taiho Oncology, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$12,309
- OGSIVEO$4,550
- VIMSELTINIB$2,183
- ROMVIMZA$555
- OPDIVO$126
How this compares
$28,153 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BraftoviEncorafenib | 32 | $543,508 |
| MektoviBinimetinib | 33 | $449,380 |
| IbrancePalbociclib | 15 | $239,689 |
| EliquisApixaban | 14 | $15,064 |
| Ondansetron Hcl | 27 | $3,079 |
| Prednisone | 68 | $430 |
| Levothyroxine Sodium | 26 | $220 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $203 |
| Gabapentin | 15 | $191 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 11 | $165 |
| Triamcinolone Acetonide | 13 | $59 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 21 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Array Biopharma IncBraftovi, Mektovi | $109 | $992,88865 claims |
| PfizerIbrance, Eliquis | $32 | $254,75329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cleveland
- Hillard LazarusCleveland$2M
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Bachar DerghamCleveland$387K
- Brian HillCleveland$316K
- Dale ShepardCleveland$314K
- Sakti ChakrabartiCleveland$301K
- Keith McCraeCleveland$215K
- Megan KruseCleveland$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.